MWNA
PRAX icon

Marshall Wace North America’s Praxis Precision Medicines PRAX Stock Holding History

Marshall Wace North America’s Portfolio PRAX Stock Details PRAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$3.12M Buy
11,233
+1,907
+20% +$517K 0.01% 626
2021
Q2 		$2.56M Sell
9,326
-11,872
-56% -$4.25M 0.01% 735
2021
Q1 		$10.4M Sell
21,198
-3,554
-14% -$2.53M 0.04% 381
2020
Q4 		$20.4M Buy
+24,752
New +$14.4M 0.09% 251

Other funds holding PRAX

Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Marshall Wace North America's PRAX Position: Q3 2021 in Review

Marshall Wace North America increased its Praxis Precision Medicines (PRAX) stake by 20% in Q3 2021, buying an estimated $517K and bringing the position to 11,233 shares worth $3.12M. The position accounts for 0.01% of the portfolio, ranked #626.

Marshall Wace North America first reported a position in PRAX in Q4 2020 and has held it in 4 quarters since. The position peaked at $20.4M in Q4 2020. 92 funds tracked by Wall St. Rank hold PRAX as of Q3 2021.

  • Marshall Wace North America held 11,233 shares of Praxis Precision Medicines worth $3.12M as of Q3 2021.
  • Marshall Wace North America bought 1,907 Praxis Precision Medicines shares in Q3 2021, an estimated $517K.
  • Praxis Precision Medicines made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #626 holding.
  • Marshall Wace North America first reported a position in Praxis Precision Medicines in Q4 2020 and has held it in 4 quarters since.
  • Marshall Wace North America's Praxis Precision Medicines position peaked at $20.4M in Q4 2020.
  • 92 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.